Pasithea Therapeutics Warrants
KTTAW
5 hedge funds and large institutions have $23.8K invested in Pasithea Therapeutics Warrants in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
88% more capital invested
Capital invested by funds: $12.7K → $23.8K (+$11.1K)
2.77% less ownership
Funds ownership: 67.45% → 64.68% (-2.8%)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$296 |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$144 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
1
Kepos Capital
New York
| $12K | – | – | – |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $9.18K | -$296 | -15,683 | -6% |
|
|
AC
3
Armistice Capital
New York
| $1.75K | – | – | – |
|
|
MG
4
Marex Group
London,
| $873 | – | – | – |
|
|
CS
5
Clear Street
New York
| $3 | +$2 | +100 | New |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$144 | -13,189 | Closed |
|
KTTAW Hedge Fund Activity: Q3 2024 in Review
5 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q3 2024, worth a combined $23.8K — up 88% from $12.7K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of KTTAW and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Clear Street, opening a new position worth an estimated $2. The largest seller was Warberg Asset Management, cutting an estimated $296.
- 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q3 2024, down from 6 in Q2 2024.
- Funds reported $23.8K of Pasithea Therapeutics Warrants stock for Q3 2024, up 88% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics Warrants positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest Pasithea Therapeutics Warrants buyer in Q3 2024 was Clear Street, an estimated $2 added.
- The largest Pasithea Therapeutics Warrants seller in Q3 2024 was Warberg Asset Management, an estimated $296 sold.
Based on aggregated 13F filings for Q3 2024.